I enjoy learning new things in the field of medicine.

Like everything I ever learned about the Kardashians, I learned against my will.

But learning medicine, and particularly science in general, is something I don't think will ever bore me.

So it's with some excitement that we now have a therapy for heart failure with preserved ejection

fractions, sometimes referred to as diastolic congestive heart failure. Yet at the same time,

I know the field of medicine and what nearly always happens in medicine is when something

slightly is beneficial and we don't have better therapies, we glorify that

therapy as a miracle. Some things are just taken out of context.

Listen, there's also situations that can be a big misunderstanding, like the time I got kicked

out of the gender reveal party for pulling down my pants. But when it comes to context in nuance, that can be particularly hard to tease out in medicine,

as we've seen through this entire pandemic.

Nuance is hard.

And if you look purely at the headlines of the double-blind, randomized phase 3 emperor-preserved trial showing a benefit

of sodium glucose transporter 2 inhibitors, we'll call them SGLT-2 inhibitors. And in this trial,

it was specifically impagliflozin. In patients with heart failure with a preserved ejection fraction,

it's fair to be a little excited, yet not overly excited.

Sometimes math and statistics can damper down the excitemental bit.

So about five out of four people are bad at math.

In the U.S. population, it seems people that are great at math

are becoming about as rare as gangster rappers going on to die of old age. And rest in peace,

Biggie, Tupac, Pop Smoke, Juice World, Mac Miller, all you, just rest in peace. But to my point of

many of us not being great at math and statistics,

...